Nasdaq exas.

MADISON, Wis., Feb. 16, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $466.3 million for the fourth quarter ended Dec. 31, 2020 and $1,491.4 million for the full year ended Dec. 31, 2020.In trading on Monday, shares of EXACT Sciences Corp. (Symbol: EXAS) entered into oversold territory, hitting an RSI reading of 28.7, after changing hands as low as $34.839 per share. By comparison ...Exact Sciences Stock Price, News & Analysis (NASDAQ:EXAS) $67.03 +3.03 (+4.73%) (As of 12/1/2023 ET) Compare Today's Range $62.76 $67.03 50-Day Range …WebExact Sciences (NASDAQ:EXAS) produces and sells diagnostic and cancer screening tests. The company is best known for its Cologuard product. That said, Exact Sciences has several other revenue ...

Sep 9, 2023 · Exact Sciences' revenue has grown rapidly in the past five years, but the bottom line hasn't made much progress. Cologuard 2.0 should help the company's top line maintain its momentum. Exact ... MADISON, Wis., Feb. 16, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has entered into an agreement to acquire Ashion Analytics, LLC (Ashion) from The ...

EXACT Sciences Corporation (NASDAQ: EXAS) was in 40 hedge funds' portfolios at the end of December. The all time high for this statistic is 43. EXAS has seen an increase in hedge fund sentiment ...

Nov 17, 2023 · Close $61.17 Key Data Bid Price and Ask Price The bid & ask refers to the price that an investor is willing to buy or sell a stock. The bid is the highest amount that a buyer is currently willing... According to the issued ratings of 16 analysts in the last year, the consensus rating for Exact Sciences stock is Moderate Buy based on the current 4 hold ratings and 12 buy ratings for EXAS. The average twelve-month price prediction for Exact Sciences is $96.56 with a high price target of $130.00 and a low price target of $73.00.Exact Sciences Co. (NASDAQ:EXAS) Insider Sells $864,835.43 in Stock marketbeat.com - October 13 at 8:39 PM: Baillie Gifford & Co. Sells 215,265 Shares of Exact Sciences Co. (NASDAQ:EXAS) marketbeat.com - October 12 at 3:16 PM: Exact Sciences upgraded at Piper Sandler on compelling entry point seekingalpha.com - October 12 at …Stock analysis for Exact Sciences Corp (EXAS:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Web

Exact Sciences (EXAS) closed the most recent trading day at $60.68, moving -0.49% from the previous trading session. This change was narrower than the S&P 500's daily loss of 2.77%. Meanwhile, the ...

17 Nov 2023 ... PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that it has ...

Nov 23, 2023 · EXACT Sciences Corporation (NASDAQ:EXAS) is a leading provider of cancer screening and diagnostic tests with a focus on early detection and prevention of colorectal cancer. It launched Cologuard ... EXACT Sciences Corporation stock price live 67.03, this page displays NASDAQ EXAS stock exchange data. View the EXAS premarket stock price ahead of the market session or assess the after hours quote.EXAS EXAS AFTER HOURS QUOTE EXAS LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, ...Exact Sciences Corporation Common Stock ... Nasdaq.com will report pre-market and after hours trades. Pre-Market trade data will be posted from 4:15 a.m. ET to 7:30 a.m. ET of the following day.Exact Sciences Corporation (EXAS) NasdaqCM - NasdaqCM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 67.03 +3.03 (+4.73%) At close: 04:00PM EST. 67.10 +0.07 (+0.10%) After hours: 07:58PM...Kevin Conroy. https://www.exactsciences.com. Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.Feb 10, 2023 · As of February 10, 2023, the average one-year price target for EXACT Sciences is $66.64. The forecasts range from a low of $35.35 to a high of $99.75. The average price target represents an ...

Get the latest Exscientia PLC (EXAI) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Nov 30, 2023 · Stock analysis for Exact Sciences Corp (EXAS:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Fintel reports that on May 10, 2023, B of A Securities maintained coverage of Exact Sciences (NASDAQ:EXAS) with a Buy recommendation.. Analyst Price Forecast Suggests 9.61% Upside. As of April 24 ...Jan 12, 2023 · Exact Sciences' valuation has been plummeting. In 2022, shares of Exact Sciences fell 36%, underperforming the S&P 500, which declined by 19%. Exact Sciences isn't near its 52-week low of $29.27 ... The public float for EXAS is 179.16M, and currently, short sellers hold a 4.07% ratio of that floaft. The average trading volume of EXAS on November 30, 2023 was 1.42M shares. EXAS) stock’s latest price update. Exact Sciences Corp. (NASDAQ: EXAS)’s stock price has increased by 0.14 compared to its previous closing price of 64.97.

Exact Sciences Corporation Common Stock (EXAS) Nasdaq Listed; ... Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.

The latest price target for Exact Sciences ( NASDAQ: EXAS) was reported by Goldman Sachs on Friday, November 3, 2023. The analyst firm set a price target for 90.00 expecting EXAS to rise to within ... The average one-year price target for EXAS / Exact Sciences Corp. is $112.948. The forecasts range from a low of $85.85 to a high of $136.5. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to ...1 Mar 2017 ... Exact sciences rings the Nasdaq Closing Bell! $EXAS #CRCcountdown.20 Okt 2023 ... PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will ...Nov 30, 2023 · Stock analysis for Exact Sciences Corp (EXAS:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Find the latest Earnings Report Date for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.Complete Exact Sciences Corp. stock information by Barron's. View real-time EXAS stock price and news, along with industry-best analysis.Nasdaq 14,305.03 +78.81(+0.55%) Russell 2000 1,859.47 +50.45(+2.79%) Crude Oil 74.22 -1.74(-2.29%) Gold 2,089.80 +32.60(+1.58%) Advertisement Exact Sciences Corporation …WebADVISORY, Feb. 27, 2018 (GLOBE NEWSWIRE) -- What: Exact Sciences Corp. (Nasdaq:EXAS), a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer, will open the Nasdaq Stock Market remotely from the Cologuard Classic, a PGA TOUR Champions event in Tucson, Arizona.The …

Turning to the calls side of the option chain, the call contract at the $60.00 strike price has a current bid of $4.20. If an investor was to purchase shares of EXAS stock at the current price ...

MADISON, Wis., Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its ...

At Stock Options Channel, our YieldBoost formula has looked up and down the EXAS options chain for the new July 8th contracts and identified one put and one call contract of particular interest ...Exact Sciences Corp. reported an EPS of $0 in its last earnings report, beating expectations of -$0.471. Following the earnings report the stock price went down -1.669%. Which hedge fund is a major shareholder of Exact Sciences Corp.?In the past year, this Zacks Rank #2 (Buy) stock has surged 88.5% against a 9.7% decline of the industry and a 18% rise of the S&P 500 composite. The renowned global medical device company has a ...EXACT SCIENCES CORP ( EXAS) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s ...Exact Sciences Corporation (NASDAQ:EXAS) Q2 2023 Earnings Call Transcript August 1, 2023 Exact Sciences Corporation beats earnings expectations. Reported EPS is $-0.45, expectations were $-0.51.In trading on Monday, shares of EXACT Sciences Corp. (Symbol: EXAS) entered into oversold territory, hitting an RSI reading of 28.7, after changing hands as low as $34.839 per share. By comparison ..."Exact Sciences Corporation (NASDAQ:EXAS) is a cancer diagnostics company whose flagship product is Cologuard, a stool-based screening test for colon cancer. The stock declined because financial ...As of February 10, 2023, the average one-year price target for EXACT Sciences is $66.64. The forecasts range from a low of $35.35 to a high of $99.75. The average price target represents an ...A month has gone by since the last earnings report for Exact Sciences (EXAS). Shares have added about 2.5% in that time frame, underperforming the S&P …Web

View Our Latest Research Report on EXAS. Exact Sciences Price Performance. Shares of NASDAQ EXAS opened at $67.29 on Tuesday. The stock has a market capitalization of $12.17 billion, a price-to ...Exact Sciences Corp. NASDAQ: EXAS is on a self-proclaimed mission to change the way cancer is detected and treated. The Madison, Wisconsin company is among the market's best price performers, advancin...One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was -4.51%, and its shares gained 38.05% of their value over the last 52 weeks. Exact Sciences Corporation (NASDAQ:EXAS) has a market ...Exact Sciences Corporation Common Stock ... Nasdaq.com will report pre-market and after hours trades. Pre-Market trade data will be posted from 4:15 a.m. ET to 7:30 a.m. ET of the following day.Instagram:https://instagram. norway sovereign wealth fundbest australian forex brokersbest gold exchangerovr+ Find the latest on short interest for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.Exact Sciences (EXAS) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $1.28 per share a year ago. These figures ... does webull have paper trading for optionstreasury rates today 6 month Importantly, Exact Sciences Corporation (NASDAQ:EXAS) does carry debt. But the more important question is: how much risk is that debt creating? Why Does Debt Bring Risk? Debt is a tool to help businesses grow, but if a business is incapable of paying off its lenders, then it exists at their mercy. If things get really bad, the lenders can take ...EXACT Sciences Corporation (NASDAQ:EXAS) is a leading provider of cancer screening and diagnostic tests with a focus on early detection and prevention of colorectal cancer. It launched Cologuard ... is your money stuck in an online savings account MADISON, Wis., Nov. 3, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $523 million for the third quarter ended September 30, 2022, compared to $456 million for the same period of 2021.EXAS NASDAQ. EXAS NASDAQ. EXAS NASDAQ. Market closed Market closed. 67.03 USD R +3.03 +4.73%. At close at Dec 1, 16:58 UTC-8. USD. No trades. See on …Web